Catalysts About Galapagos Galapagos is a biotech company that is repositioning itself as a lean, cash rich platform focused on external business development and a limited internal pipeline. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Galapagos Galapagos is repositioning as a capital rich, business development driven biotech company focused on acquiring and advancing clinically derisked assets. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Galapagos Galapagos is a biotechnology company focused on using its substantial capital base and deal-making expertise to build a differentiated, late stage therapeutic pipeline. What are the underlying business or industry changes driving this perspective?Read more
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
